The recent significant progress in immuno-oncology is based on the use of immune check-point inhibitors, which can break the local intratumoural immunosuppression by blocking the immune response inhibition pathways mediated by the PD-1/PD-L1 interaction.1 Immune check-point inhibitors are mainly effective in patients with immunogenic tumours, such as tumours with an important infiltration by tumour specific T cells (Tumour Infiltrating Lymphocytes; TILs). Here, CD274 is linked to neoplasm.